tiprankstipranks
Advertisement
Advertisement

BEAM Stock Latest News

Clear Street sees buying opportunity for Beam Therapeutics after study update
The FlyClear Street sees buying opportunity for Beam Therapeutics after study update
2h ago
BEAM
Beam Therapeutics: BEAM-302’s Differentiated AATD Profile and Accelerated Path Support Buy Rating and $80 Target
PremiumRatings
Beam Therapeutics: BEAM-302’s Differentiated AATD Profile and Accelerated Path Support Buy Rating and $80 Target
4h ago
BEAM
Beam Therapeutics announces safety, efficacy data from BEAM-302 trial
PremiumThe Fly
Beam Therapeutics announces safety, efficacy data from BEAM-302 trial
7h ago
BEAM
Beam Therapeutics Restructures Base-Editing Licensing After Bio Palette Exit
PremiumCompany Announcements
Beam Therapeutics Restructures Base-Editing Licensing After Bio Palette Exit
20d ago
8K
BEAM
Beam Therapeutics Earnings Call Highlights PKU Pivot
PremiumCompany Announcements
Beam Therapeutics Earnings Call Highlights PKU Pivot
21d ago
BEAM
Beam Therapeutics: Advancing Interventional Genetics With Strong Balance Sheet and Multiple Near-Term Catalysts Supporting Buy Rating
PremiumRatingsBeam Therapeutics: Advancing Interventional Genetics With Strong Balance Sheet and Multiple Near-Term Catalysts Supporting Buy Rating
23d ago
BEAM
Beam Therapeutics price target raised to $26 from $22 at RBC Capital
Premium
The Fly
Beam Therapeutics price target raised to $26 from $22 at RBC Capital
28d ago
BEAM
Beam Therapeutics price target raised to $65 from $57 at Wedbush
Premium
The Fly
Beam Therapeutics price target raised to $65 from $57 at Wedbush
28d ago
BEAM
Beam Therapeutics price target raised to $75 from $74 at Canaccord
PremiumThe Fly
Beam Therapeutics price target raised to $75 from $74 at Canaccord
28d ago
BEAM
Beam Therapeutics: Clinical Momentum, Platform Validation, and De‑Risked Financing Support Buy Rating and $47 Target
PremiumRatings
Beam Therapeutics: Clinical Momentum, Platform Validation, and De‑Risked Financing Support Buy Rating and $47 Target
28d ago
BEAM
Beam Therapeutics price target raised to $47 from $45 at BofA
PremiumThe Fly
Beam Therapeutics price target raised to $47 from $45 at BofA
29d ago
PFE
BEAM
Kyverna Therapeutics appoints Sravan Emany, Andrew Miller to board
PremiumThe Fly
Kyverna Therapeutics appoints Sravan Emany, Andrew Miller to board
29d ago
BEAM
KYTX
Beam Therapeutics announces $500M financing facility
PremiumThe FlyBeam Therapeutics announces $500M financing facility
29d ago
BEAM
Beam Therapeutics Secures $500 Million Credit Facility
Premium
Company Announcements
Beam Therapeutics Secures $500 Million Credit Facility
29d ago
8K
BEAM
Beam Therapeutics reports Q4 EPS $2.33 vs ($1.09) last year
Premium
The Fly
Beam Therapeutics reports Q4 EPS $2.33 vs ($1.09) last year
29d ago
BEAM
Walmart downgraded, Etsy upgraded: Wall Street’s top analyst calls
PremiumThe Fly
Walmart downgraded, Etsy upgraded: Wall Street’s top analyst calls
1M ago
GE
RS
Beam Therapeutics initiated with a Buy at Canaccord
PremiumThe Fly
Beam Therapeutics initiated with a Buy at Canaccord
1M ago
BEAM
Beam Therapeutics initiated with a Buy at Canaccord
PremiumThe Fly
Beam Therapeutics initiated with a Buy at Canaccord
1M ago
BEAM
Cathie Wood Loads Up on Momentum Stocks after Earnings Rally. Should You Follow?
PremiumMarket News
Cathie Wood Loads Up on Momentum Stocks after Earnings Rally. Should You Follow?
1M ago
PD
TER
Beam Therapeutics Secures Standby License for Key Patents
PremiumCompany AnnouncementsBeam Therapeutics Secures Standby License for Key Patents
1M ago
8K
BEAM
Beam Therapeutics announces upcoming board member resignation
Premium
Company Announcements
Beam Therapeutics announces upcoming board member resignation
2M ago
8K
BEAM
Beam Therapeutics participates in a conference call with William Blair
Premium
The Fly
Beam Therapeutics participates in a conference call with William Blair
2M ago
BEAM

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >